QQQ $ 495.80 $ 5.12 (1.04 %)
DIA $ 393.71 $ 0.87 (0.22 %)
SPY $ 554.29 $ 3.18 (0.58 %)
TLT $ 92.56 $ 0.76 (0.83 %)
GLD $ 220.89 $ 2.94 (1.35 %)
$ na
-- x --
-- x --
-- - --
nm - nm
0
na
na
nm
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 psyched-the-50-publicly-listed-psychedelics-companies-atais-new-subsidiary-pharmather-gets-new-orphan-drug-designation

The Week In Psychedelics

 there-are-now-50-psychedelics-companies-listed-in-the-us---here-they-are

Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking in...

 6-psychedelic-stocks-with-buy-rating-why-are-they-good-investments

This article by Jason Najum was originally published on Microdose Psychedelic Insights and appears here with permission. The p...

 psyched-mindmeds-nasdaq-debut-pharmadrug-gets-orphan-drug-designation-for-dmt-numinus-launches-clinical-trial-of-naturally-derived-psilocybin

PharmaDrug Inc. (CSE: BUZZ) (Pink: LMLLF) announced an FDA-granted Orphan Drug Designation to its wholly owned subsidiary Sairi...

 numinus-launches-clinical-trial-of-naturally-derived-psilocybin

Numinus Wellness (Pink: LKYSF) (TSXV: NUMI) announced the launch of a new clinical trial that will add information to an indust...